Search Results

MiNA Therapeutics today announced a research collaboration and licensing agreement option with Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters: Kyoto; President: Toru Nakai), an innovation-driven Japanese-based pharmaceutical company focused on disease areas of high unmet medical need.

NS Pharma, Inc. (NS Pharma) announced that its parent company, Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) – headquartered in Kyoto, Japan, entered into a joint research agreement with MiNA Therapeutics – headquartered in London, United Kingdom, to develop nucleic acid drugs for the potential treatment of intractable and rare diseases of the central nervous system.

MiNA Therapeutics Limited announced today that it will present new pre-clinical data for its lead RNA activation program targeting fetal hemoglobin (HbF) at the Keystone Symposia’s Delivery of Nucleic Acid Therapeutics Conference in Banff, Alberta, Canada.

MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, highlights preclinical research presented by academic partners at the annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.

MiNA Therapeutics today announced a multi-target research collaboration and option licensing agreement with BioMarin Pharmaceutical Inc.

MiNA Therapeutics Limited will present positive updated biomarker data from its Phase 1a/b TIMEPOINT study of MTL-CEBPA in combination with the anti-PD1 checkpoint inhibitor, pembrolizumab, in adults with advanced solid tumors at the annual meeting of the American Association of Cancer Research (AACR) in Orlando, Florida.

ACELYRIN, INC. announced that ACELYRIN’s founder Shao-Lee Lin, M.D., Ph.D. has stepped down as Chief Executive Officer and that Mina Kim, chief legal and administrative officer at ACELYRIN, has been appointed Chief Executive Officer and to the company’s Board of Directors.

MTL-STING is the second drug candidate to be advanced from the Company’s internal pipeline of small activating RNA therapeutics STING is a highly validated drug target that plays a key role in immune evasion in cancer MiNA Therapeutics Limited, the pioneer in small activating RNA therapeutics, presents preclinical proof of mechanism data on MTL‑STING as a novel cancer immunotherapy.

MiNA Therapeutics Limited, the pioneer in small activating RNA therapeutics, announces that Eli Lilly and Company has entered into a definitive agreement under which it will make a direct equity investment in MiNA.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system